Patent ID: 8778993
Filing Date: 2014-07-15
Classification: A61K,A61P

Abstract:
1. A method for the treatment of disease conditions in a patient by downregulating the expression and/or activity of components selected from the group consisting of protein kinase C, nuclear factor kappa-B, ubiquitin-conjugating enzymes and components of 26S proteasome, the method comprising administering a composition comprising beta-hydroxy-beta-methylbutyrate, its salts, metabolites or derivatives thereof to the patient, and wherein the composition is substantially lacking in free amino acids; and wherein the disease conditions are selected from one or more of cancer, cachexia, age-associated wasting, wasting associated with long-term hospitalisation, human immunodeficiency virus/acquired immunodeficiency syndrome, arthritis, trauma, liver disease, Crohn's disease, inflammatory bowel disease, renal insufficiency and chronic obstructive pulmonary disease.